Skip Navigation

Erratum for Wagner et al., J. Natl. Cancer Inst. 91 (10) 847-853.
JNCI Journal of the National Cancer Institute 2000 92(2):164-165; doi:10.1093/jnci/92.2.164
© 2000 by Oxford University Press
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 2, 164-165, January 19, 2000
© 2000 Oxford University Press

Incremental Costs of Enrolling Cancer Patients in Clinical Trials: a Population-Based Study

Erratum: "Incremental Costs of Enrolling Cancer Patients in Clinical Trials: a Population-Based Study" by Wagner et al. (J Natl Cancer Inst 1999;91:847-53 [Issue 10]). An error in the costing algorithm resulted in too many recorded ancillary services. Corrected results are presented in amended Tables 3,Go 4,Go and 5Go and in Figs. 1Go and 2.Go Aggregate per-patient costs were substantially lower than previously reported for both case patients (on trials) and control patients (off trials) over the entire follow-up period. However, the differences between case patients and control patients remained small. Trial enrollees incurred modestly higher costs (3.5%-13% after adjustment for censoring) over follow-up periods ranging from 1 to 5 years. The mean cumulative 5-year cost in 1995 inflation-adjusted U.S. dollars among trial enrollees after adjustment for censoring was $28 853 compared with $27 870 for control patients. After 1 year, trial enrollee costs were $16 803 compared with $14 896 for control patients. For the 34 matched pairs in which both subjects died during the study period, case patients incurred higher costs consistently over the last year of life. These corrected results continue to suggest that cancer chemotherapy trials may not add much to the costs of treating cancer. The authors regret the error.


View this table:
[in this window]
[in a new window]
  		Table 3. Mean (median) costs for various times from index date (1995 U.S. dollars)

 

View this table:
[in this window]
[in a new window]
  		Table 4. Monthly cost estimates (1995 U.S. dollars)

 

View this table:
[in this window]
[in a new window]
  		Table 5. Mean (median) costs incurred (in 1995 U.S. dollars) within various times from death

 


View larger version (16K):
[in this window]
[in a new window]
  		Fig. 1. Five-year cost comparison (log scales) for various case and control pairs present in U.S. dollars adjusted to 1995 levels.

 


View larger version (12K):
[in this window]
[in a new window]
  		Fig. 2. Mean cumulative cost derived by the Kaplan-Meier sample average estimate. Data for the cost are expressed in U.S. dollars adjusted to 1995 levels. Dashed line = case patients. Solid line = control patients. The 95% confidence interval at 12 months after trial entry was $12 873-$20 733 for case patients and $10 922-$18 870 for control patients. At 60 months after trial entry, the 95% confidence interval was $23 250-$34 458 for case patients and $21 498-$34 242 for control patients. Confidence intervals were based on estimates of variance obtained by the bootstrap method involving 10 000 simulated samples.

 


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
H. S. Kok, N. C. Onland-Moret, K. M. van Asselt, C. H. van Gils, Y. T. van der Schouw, D. E. Grobbee, and P. H.M. Peeters
No association of estrogen receptor {alpha} and cytochrome P450c17{alpha} polymorphisms with age at menopause in a Dutch cohort
Hum. Reprod., February 1, 2005; 20(2): 536 - 542.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. P. Goldman, S. H. Berry, M. S. McCabe, M. L. Kilgore, A. L. Potosky, M. L. Schoenbaum, M. Schonlau, J. C. Weeks, R. Kaplan, and J. J. Escarce
Incremental Treatment Costs in National Cancer Institute-Sponsored Clinical Trials
JAMA, June 11, 2003; 289(22): 2970 - 2977.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. A. Presant
Patient Costs on Clinical Trials
J Natl Cancer Inst, September 6, 2000; 92(17): 1441 - 1442.
[Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?